Just reported
Q3 2026 results
From Biocryst Pharmaceuticals, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Revenue
Actual
$180.3M
+13% y/y ↑
-17% q/q ↓
EPS, GAAP
Actual
$0.14
+133% y/y ↑
-53% q/q ↓
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $180.3M | $159.4M | +13.11% |
| Profit | $37.9M | $12.9M | +193.95% |
| Profit per share | $0.14 | $0.06 | +133.33% |
| Free Cash Flow | $32.8M | $40.3M | -18.69% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingBiocryst Pharmaceuticals, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$8.57
Nov 3, 2026
Close after
$7.63
Nov 5, 2026
Move
-10.97%
15.36M shares traded, against a normal 5.24M
What Biocryst Pharmaceuticals, Inc. does
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Biocryst Pharmaceuticals, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
